fda melanotan Melanotan-1 10mg Peptide MELANOTAN II

This modification is also referred to as the Drug Affinity Complex (DAC) and potentially supports covalent binding to albumin, significantly extending the peptides half-life and reducing proteolytic degradation

Results of the trial showed "Adolescent and adult patients with vitiligo achieved substantial facial and total body re-pigmentation within 24 to 52 weeks of therapy." Half of all participants had 75% improvement of their facial vitiligo after one year using the study's measurement of repigmentation

The work is mostly preclinical, so any human benefit remains unconfirmed

Unless otherwise noted, results reflect bmiMD patient experiences rather than public clinical studies.